Mylan Speciality Lp Drug Patent Portfolio

Mylan Speciality Lp owns 2 orange book drugs protected by 8 US patents Given below is the list of Mylan Speciality Lp's drug patents along with their expiration dates.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7645801 Reduced irritant enema for treatment of inflammatory bowel disease (IBD) 24 Jul, 2027
Active
US8168620 Combination of azelastine and steroids 24 Aug, 2026
Active
US8168620 Combination of azelastine and steroids 24 Feb, 2026
Active
US8163723 Combination of azelastine and steroids 29 Feb, 2024 Expired
US9259428 Combination of azelastine and fluticasone for nasal administration 13 Dec, 2023 Expired
US8163723 Combination of azelastine and steroids 29 Aug, 2023 Expired
US9259428 Combination of azelastine and fluticasone for nasal administration 13 Jun, 2023 Expired
US9901585 Combination of azelastine and fluticasone for nasal administration 13 Jun, 2023 Expired


Given below is the list of recent legal activities going on the following drug patents of Mylan Speciality Lp.

Activity Date Patent Number
Patent litigations
Expire Patent 03 Jun, 2024 US8168620 (Litigated)
Expire Patent 27 May, 2024 US8163723 (Litigated)
Expire Patent 25 Mar, 2024 US9259428 (Litigated)
Maintenance Fee Reminder Mailed 18 Dec, 2023 US8168620 (Litigated)
Maintenance Fee Reminder Mailed 11 Dec, 2023 US8163723 (Litigated)
Maintenance Fee Reminder Mailed 09 Oct, 2023 US9259428 (Litigated)
Payment of Maintenance Fee, 4th Year, Large Entity 17 Aug, 2021 US9901585
Payment of Maintenance Fee, 12th Year, Large Entity 29 Jun, 2021 US7645801
Request for Trial Denied 31 Jul, 2020 US8168620 (Litigated)
Request for Trial Denied 31 Jul, 2020 US8163723 (Litigated)
Request for Trial Denied 31 Jul, 2020 US9901585
Request for Trial Denied 31 Jul, 2020 US9259428 (Litigated)
Petition Requesting Trial 31 Jan, 2020 US9901585
Petition Requesting Trial 31 Jan, 2020 US8163723 (Litigated)
Petition Requesting Trial 31 Jan, 2020 US8168620 (Litigated)


Mylan Speciality Lp's Drug Patent Litigations

Mylan Speciality Lp's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Apr 23, 2008, against patent number US7645801. The petitioner , challenged the validity of this patent, with Bala VENKATARAMAN et al as the respondent. Click below to track the latest information on how companies are challenging Mylan Speciality Lp's patents.

Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US8163723 January, 2020 Terminated-Denied
(31 Jul, 2020)
Cipla Limited GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
US8168620 January, 2020 Terminated-Denied
(31 Jul, 2020)
Cipla Limited GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
US9259428 January, 2020 Terminated-Denied
(31 Jul, 2020)
Cipla Limited GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
US9901585 January, 2020 Terminated-Denied
(31 Jul, 2020)
Cipla Limited GlaxoSmithKline Consumer Healthcare Holdings (US) LLC
US8168620 February, 2017 Terminated-Settled
(21 May, 2018)
Cipla Limited Argentum Pharmaceuticals LLC
US7645801 April, 2008 Decision
(08 Dec, 2008)
Bala VENKATARAMAN et al


Mylan Speciality Lp Drug Patents' Oppositions Filed in EPO

Mylan Speciality Lp drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 14, 2010, by Glaxo Group Limited. This opposition was filed on patent number EP03738280A. Click below to reveal the latest opposition data.


Application Filing Date Opposition Party Legal Status
Patent litigations
EP09075100A Apr, 2016 Sanovel IIaç San. ve Tic. A.S. Revoked
EP09075101A Oct, 2014 Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi Revoked
EP09075101A Oct, 2014 Sanovel IIaç San. ve Tic. A.S. Revoked
EP03738280A Jan, 2010 Glaxo Group Limited Revoked


Mylan Speciality Lp's Family Patents

Mylan Speciality Lp drugs have patent protection in a total of 27 countries. It's US patent count contributes only to 19.4% of its total global patent coverage. 7 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree.

Family Patents



Mylan Speciality Lp Drug List

Given below is the complete list of Mylan Speciality Lp's drugs and the patents protecting them.


1. Dymista

Dymista is protected by 7 patents, out of which 5 have expired. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US8168620
(Pediatric)
Combination of azelastine and steroids 24 Aug, 2026
(1 year, 2 months from now)
Active
US8168620 Combination of azelastine and steroids 24 Feb, 2026
(8 months from now)
Active
US8163723
(Pediatric)
Combination of azelastine and steroids 29 Feb, 2024
(1 year, 3 months ago)
Expired
US9259428
(Pediatric)
Combination of azelastine and fluticasone for nasal administration 13 Dec, 2023
(1 year, 6 months ago)
Expired
US8163723 Combination of azelastine and steroids 29 Aug, 2023
(1 year, 9 months ago)
Expired
US9259428 Combination of azelastine and fluticasone for nasal administration 13 Jun, 2023
(2 years ago)
Expired
US9901585 Combination of azelastine and fluticasone for nasal administration 13 Jun, 2023
(2 years ago)
Expired

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Dymista's drug page


2. Sfrowasa

Sfrowasa is protected by 1 patent, which is still active. Check out its patent list below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
US7645801 Reduced irritant enema for treatment of inflammatory bowel disease (IBD) 24 Jul, 2027
(2 years from now)
Active

Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Sfrowasa's drug page


Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List